Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
PS 2 patients with advanced NSCLC might not benefit from cisplatin combination therapy.
A possible predictor of treatment response was identified for patients with OCD undergoing anterior cingulotomy. Further research, utilizing a prospective design, is indicated to determine the validity and reliability of this finding. If confirmed, an index for noninvasively predicting response to cingulotomy for OCD would be of great value.